Pheasants are generally listed on the market from August to December each year. In order to increase the breeding efficiency, pheasants can be marketed through anti-season farming from January to July to obtain better economic benefits. The method is as follows: To obtain pheasant species that produce eggs in two seasons: The source of these chicken species can be purified from the pheasant seedlings that are hatched at the latest in the autumn each year. Generally, the pheasant seedlings hatched in late October after 7 months The rearing of the pheasant, which was opened in May until January, was generally started in September and stopped until March of the following year. Egg production per hen ranges from 100 to 120 pieces. These hatched chicks are listed on the market for three or four months after hatching. This is exactly the best-selling season for commercial pheasants. At the same time, the pheasants hatched from October to February of the following year can be used as a counter-season breeding pheasant population in the next year. Keeping off-season pheasant breeder chickens: Roosters are best kept one month ahead of schedule to allow them to mature synchronously at the time of hens production and to facilitate mating. At the same time, the roosters need to avoid inbreeding, which is beneficial to improving hatching rate, reducing weak chicks and improving breeds. The breeding stage can be used for laying hens, plus fish meal, vitamin A, vitamin D and other additives. It can be kept indoors during the winter and sunlight for 16 hours. Diagnostic reagents can be divided into two categories: in vivo diagnostic reagents and in vitro diagnostic reagents. It is mostly a reagent for detection by the reaction between antigen and antibody. Urine Rapid Test Kit,Rapid Test Kit 6-Panel,Toxoplasma rapid test kits,Fecal Occult Blood Test Jilin Sinoscience Technology Co. LTD , https://www.jlgkscience.com
A: Classification of in vitro diagnostic reagents:
1. In vitro biodiagnostic reagents managed as drugs include:
1. Blood type and tissue type reagents;
2. Microbial antigen, antibody and nucleic acid detection reagents;
3. Tumor marker reagents;
4. Immunohistochemistry and human tissue cell reagents;
5. Human genetic testing reagents;
6. Biochips;
7. Allergy diagnostic reagents.
2. In vitro reagents managed as medical devices include:
1. Clinical basic test reagents;
2. Clinical chemistry reagents;
3. Blood gas and electrolyte determination reagents;
4. Vitamin determination reagents;
5. Cell histochemical stains;
6. Autoimmune diagnostic reagents;
7. Microbiological test reagents.
B: According to medical test items, clinical diagnostic reagents can be roughly divided into clinical chemical test reagents, immunology and
Serological testing reagents, hematological and cytogenetic testing reagents, microbiological testing reagents, body fluid excretion
Detection reagents, genetic diagnosis reagents, etc. Among them, the market share of clinical chemistry
The largest, close to 34%; followed by the immunology market, accounting for about 29%. Novel immunodiagnostic reagents and genetic diagnostic tests
The reagent was developed in the late 1980s, and it is the most common diagnostic reagent for all current diagnostic reagents, regardless of technology or market.
The fastest growing product.